Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
205.41B
Market cap205.41B
Price-Earnings ratio
11.38
Price-Earnings ratio11.38
Dividend yield
2.64%
Dividend yield2.64%
Average volume
10.12M
Average volume10.12M
High today
$46.74
High today$46.74
Low today
$46.04
Low today$46.04
Open price
$46.34
Open price$46.34
Volume
6.22M
Volume6.22M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 11h
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

Key Points Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a c...

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Simply Wall St 1d
Novo Nordisk Stock May Be Below Fair Value After GLP 1 Legal News

Novo Nordisk stock has had a difficult three year stretch, yet current valuation checks suggest the market may now be pricing it more cautiously than its fundam...

Novo Nordisk Stock May Be Below Fair Value After GLP 1 Legal News
TipRanks 2d
Novo Nordisk Advances New Injectable Obesity Drug in Key Phase 3 Trial

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study, officially titled “A Placebo-controlled Comparability Study to Compare Two P...

More NVO News

TipRanks 2d
Novo Nordisk Advances New Obesity Drug NNC0721-8060 Into First Human Trial

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodyna...

TipRanks 2d
Novo Nordisk Refines Its Obesity Pipeline With New Cagrilintide Study Update

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study titled “Investigation of Pharmacokinetics of Two Different Presentations of C...

Nasdaq 2d
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?

Amgen’s AMGN key pipeline candidate MariTide is a closely watched drug in the obesity market. The drug can give Amgen exposure to one of the industry's fastest-...

AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
TipRanks 2d
Novo Nordisk owner, Quantum Foundry establish chip fab facility in Copenhagen

Quantum Foundry Copenhagen and the Novo Nordisk (NVO) Foundation announce plans to establish a new 5,300 m^2 quantum chip fabrication facility in Copenhagen. Th...

TipRanks 4d
Pharma Giant Novo Nordisk Stock Jumps Even as Deutsche Bank Repeats Sell Call

Shares of Novo Nordisk (NVO) climbed by 4% to about $47 per share on Wednesday morning even after Deutsche Bank (DB) reaffirmed its Sell rating on the Danish ph...

TipRanks 6d
Novo Nordisk Advances DKK 15 Billion Share Buyback Programme Through Late August 2026

Novo Nordisk ( (NVO) ) just unveiled an update. Novo Nordisk, a Danish healthcare company specialising in treatments for serious chronic diseases such as diabe...

The Motley Fool 7d
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new cla...

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.